Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Biochemistry (Mosc) ; 88(6): 810-822, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37748877

RESUMEN

Normalization of secretory activity and differentiation status of mesenchymal cells, including fibroblasts, is an important biomedical problem. One of the possible solutions is modulation of unfolded protein response (UPR) activated during fibroblast differentiation. Here, we investigated the effect of phytohormones on the secretory activity and differentiation of cultured human skin fibroblasts. Based on the analysis of expression of genes encoding UPR markers, abscisic acid (ABA) upregulated expression of the GRP78 and ATF4 genes, while gibberellic acid (GA) upregulated expression of CHOP. Evaluation of the biosynthetic activity of fibroblasts showed that ABA promoted secretion and synthesis of procollagen I and synthesis of fibronectin, as well as the total production of collagen and non-collagen proteins of the extracellular matrix (ECM). ABA also stimulated the synthesis of smooth muscle actin α (α-SMA), which is the marker of myofibroblasts, and increased the number of myofibroblasts in the cell population. On the contrary, GA increased the level of fibronectin secretion, but reduced procollagen I synthesis and the total production of the ECM collagen proteins. GA downregulated the synthesis of α-SMA and decreased the number of myofibroblasts in the cell population. Our results suggest that phytohormones modulate the biosynthetic activity of fibroblasts and affect their differentiation status.


Asunto(s)
Fibronectinas , Reguladores del Crecimiento de las Plantas , Humanos , Fibronectinas/genética , Fibronectinas/metabolismo , Fibronectinas/farmacología , Reguladores del Crecimiento de las Plantas/metabolismo , Reguladores del Crecimiento de las Plantas/farmacología , Procolágeno/genética , Procolágeno/metabolismo , Procolágeno/farmacología , Células Cultivadas , Fibroblastos/metabolismo , Miofibroblastos/metabolismo , Diferenciación Celular , Colágeno , Proteínas de la Matriz Extracelular/metabolismo , Actinas/metabolismo , Respuesta de Proteína Desplegada
2.
Acta Derm Venereol ; 103: adv4475, 2023 Apr 06.
Artículo en Inglés | MEDLINE | ID: mdl-37021598

RESUMEN

Keloids are skin tumours caused by aberrant growth of dermal fibroblasts. Cellular senescence contributes to aging and various pathological conditions, including cancer, atherosclerosis, and fibrotic diseases. However, the effects of cellular senescence and senolytic drugs on keloids remain largely unknown. This study investigated senescent fibroblasts in keloids and assessed the effects of dasatinib on these cells. Tissues acquired from keloid removal surgery were analysed for senescence-associated ß-galactosidase-positive cells, p16 expression, and the effects of dasatinib treatment on keloids. Keloid tissue was xenotransplanted into mice, and the effect of intralesional dasatinib injection on keloid growth was observed. The results showed that the numbers of ß-galactosidase-positive and p16-expressing cells were higher in the keloids compared with in the controls. Dasatinib induced selective clearance of senescent cells and decreased procollagen expression in cultured keloid fibroblasts. In this xenotransplant keloid mouse model, intralesional injection of dasatinib reduced gross keloid tissue weight and the expression of both procollagen and p16. In addition, dasatinib-treated keloid fibroblasts conditioned medium reduced procollagen and p16 expression in cultured keloid fibroblasts. In conclusion, these results suggest that an increased number of senescent fibroblasts may play an important role in the pathogenesis of keloids. Therefore, dasatinib could be an alternative treatment for patients with keloids.


Asunto(s)
Queloide , Animales , Ratones , Queloide/tratamiento farmacológico , Queloide/metabolismo , Queloide/patología , Procolágeno/metabolismo , Procolágeno/farmacología , Dasatinib/metabolismo , Dasatinib/farmacología , Dasatinib/uso terapéutico , Senescencia Celular , Fibroblastos/metabolismo , Fibroblastos/patología , Células Cultivadas
3.
Acta Orthop Traumatol Turc ; 57(1): 17-22, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-36939360

RESUMEN

OBJECTIVE: The aim of this study was to evaluate the effects of vitamin K2 on fracture healing. METHODS: Twenty-four 6-week-old male Wistar albino rats that had open tibia fractures induced were included in this study. They were divided into 2 groups of 12, a group that had vitamin K2 administered over 30 consecutive days and a control group. After 30 days, the rats were sacrificed, and from each group, 6 tibiae were selected for biomechanical testing to examine the mechanical strength of the callus tissue using the Instron 3-point bending test and 6 tibiae were selected for histological analysis to examine the density and organization of callus tissue using Allen's grading system and Huo et al's grading system. Furthermore, weekly x-rays were taken to evaluate bone union described by Lane and Sandhu, and osteocalcin, procollagen I N-terminal propeptide, and procollagen I C-terminal propeptide were examined in blood samples taken by intracardiac puncture during sacrification. RESULTS: Breaking force (P = .047), breaking time (P = .019), stiffness (P = .039), fracture strength (P = .041), and Young's modulus (P = .032) showed a statistically significant increase in the K2 group. Procollagen I C-terminal propeptide (P = .024), procollagen I N-terminal propeptide (.047), and osteocalcin (.048) levels were significantly higher in the K2 group compared to the control group. Furthermore, 3rd-week x-rays showed higher bone union scores according to the Lane and Sandhu method in the K2 group (P = .014). However, the histological grading systems of Allen and Huo et al did not show statistically significant differences between groups (P = .086, P = .07, respectively). CONCLUSION: In light of these findings, it could be concluded that vitamin K2 has a significant positive effect on fracture healing.


Asunto(s)
Curación de Fractura , Fracturas de la Tibia , Animales , Ratas , Masculino , Vitamina K 2/farmacología , Tibia/diagnóstico por imagen , Tibia/patología , Osteocalcina/farmacología , Procolágeno/farmacología , Ratas Wistar , Fracturas de la Tibia/diagnóstico por imagen , Fracturas de la Tibia/tratamiento farmacológico , Fenómenos Biomecánicos
4.
Int J Cardiol ; 377: 86-88, 2023 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-36738846

RESUMEN

BACKGROUND: Spironolactone might improve the prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFpEF), but the mechanisms by which it acts are uncertain. Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) reflect the synthesis of type I collagen and correlate well with histologically proven cardiac fibrosis. AIMS: To investigate the effect of spironolactone on serum PICP concentration in patients with stage B and C HFpEF across three trials (HOMAGE, ALDO-DHF, and TOPCAT) for which measurements of serum PICP were available. METHODS: Random-effects meta-analysis. RESULTS: A total of 1038 patients with PICP measurements available both at baseline and 9-12 months were included in this analysis: 488 (47.0%) from HOMAGE, 386 (37.2%) from ALDO-DHF, and 164 (15.8%) from TOPCAT. The median (percentile25-75) serum PICP was 98 (76-128) ng/mL. Compared to placebo or usual care, administration of spironolactone for 9 to 12 months reduced serum PICP by -7.4 ng/mL, 95%CI -13.9 to -0.9, P-value =0.02. The effect was moderately heterogeneous (I2 = 64%) with the most pronounced effect seen in TOPCAT where PICP was reduced by -27.0 ng/mL, followed by HOMAGE where PICP was reduced by -8.1 ng/mL, and was least marked in ALDO-DHF where PICP changed by -2.9 ng/mL. The association between spironolactone and serum PICP was not mediated substantially by blood pressure. CONCLUSIONS: Spironolactone reduced serum concentrations of PICP in patients with HFpEF with different severity and stages of disease. These findings are consistent with spironolactone having an anti-fibrotic effect.


Asunto(s)
Insuficiencia Cardíaca , Espironolactona , Humanos , Espironolactona/uso terapéutico , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/tratamiento farmacológico , Volumen Sistólico , Función Ventricular Izquierda , Ensayos Clínicos Controlados Aleatorios como Asunto , Fibrosis , Procolágeno/farmacología , Procolágeno/uso terapéutico , Fragmentos de Péptidos
5.
Clin Orthop Relat Res ; 481(4): 822-834, 2023 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-36724201

RESUMEN

BACKGROUND: Joint contractures occur frequently after trauma or immobilization, but few reliable treatments are available. Extracorporeal shock wave therapy (ESWT) is often used for various musculoskeletal conditions, but whether it is effective for treating joint contractures and the mechanisms through which it might work for that condition remain unclear. QUESTIONS/PURPOSES: Using a rat model, we asked, does ESWT (1) inhibit the progression of knee contracture, (2) ameliorate histopathologic joint changes, and (3) improve serum and myofascial fibrosis-related factors? We also asked, (4) what is the possible mechanism by which ESWT inhibits knee contracture? METHODS: Thirty-two male Sprague-Dawley rats (12 weeks old and weighing 300 to 400 g) were randomly separated into two groups: control group (eight rats) and noncontrol group (24) in the first week. Rats in the control group were kept free in cages for 4 weeks, and the right lower limbs of the rats in the noncontrol group were immobilized in plaster for 4 weeks. ROM was then measured for each rat with or without 4 weeks of immobilization. After ROM measurement, rats in the noncontrol group were randomly separated into three groups: immobilization group (eight rats), remobilization group (eight rats), and remobilization with ESWT group (eight rats) at Week 4. Knee contracture was induced in rats by fixing the right knee with a plaster cast as in a previous study. The plaster cast was removed after 4 weeks; knee contracture was established when passive ROM was decreased and dysfunction such as abnormal gait occurred. Subsequently, rats with a remobilized joint contracture were treated with or without ESWT for 15 days (on Days 5, 10, and 15). The therapeutic effect was examined using ROM, joint diameter (as an indication of swelling), histopathologic changes, and the levels of fibrosis-related extracellular matrix component factors (hyaluronic acid, serum procollagen peptide, and laminin). The effect of ESWT on fibrosis protein was also evaluated using immunohistochemistry, quantitative polymerase chain reaction (qPCR), and Western blot. The expressions of factors in the TGF-ß/SMADs pathway were also determined using Western blot and qPCR. RESULTS: ESWT mitigated immobilization-induced knee contracture in rats by improving ROM (immobilization versus remobilization with ESWT: 53° ± 8° versus 32° ± 8° [95% confidence interval 13° to 30°]; p < 0.001) and joint swelling (immobilization versus remobilization with ESWT: 8 ± 0.8 cm versus 6 ± 0.3 cm [95% CI 0.4 to 2.2 cm]; p = 0.01). Histopathologic features of remission were alleviated after ESWT (immobilization versus remobilization with ESWT: thickness of the knee space: 0.2 ± 0.03 mm versus 0.6 ± 0.01 mm [95% CI -0.49 to -0.33 mm]; p < 0.001. On Masson staining, the positive expression area, which indicates collagen fiber deposition, was 24% ± 5% versus 9% ± 2% ([95% CI 10% to 21%]; p < 0.001). ESWT improved the serum fibrosis factors of hyaluronic acid, procollagen peptide, and laminin (immobilization versus remobilization with ESWT: hyaluronic acid: 412 ± 32 versus 326 ±15 ng/mL [95% CI 29 to 144 ng/mL]; p = 0.003; serum procollagen peptide: 19 ± 1 versus 12 ±1 ng/mL [95% CI 3 to 11 ng/mL]; p < 0.001; laminin: 624 ± 78 versus 468 ±9 ng/mL [95% CI 81 to 231 ng/mL]; p = 0.006) and myofascial factors of α-SMA and Type I collagen associated with immobilization-induced contractures. CONCLUSION: The findings suggest that ESWT improved joint contracture by inhibiting the TGF-ß1/SMADs signaling pathway in rats. CLINICAL RELEVANCE: This work suggests ESWT may be worth exploring in preliminary research in humans to determine whether it may be a treatment option for patients with nontraumatic knee contractures. If the mechanism of ESWT can be confirmed in humans, ESWT might be a therapy for diseases involved in the TGF-ß1/SMADs signaling pathway, such as hypertroic scarring and scleroderma.


Asunto(s)
Contractura , Tratamiento con Ondas de Choque Extracorpóreas , Humanos , Ratas , Masculino , Animales , Factor de Crecimiento Transformador beta1/metabolismo , Factor de Crecimiento Transformador beta1/farmacología , Factor de Crecimiento Transformador beta1/uso terapéutico , Ácido Hialurónico , Laminina/farmacología , Laminina/uso terapéutico , Procolágeno/farmacología , Procolágeno/uso terapéutico , Ratas Sprague-Dawley , Articulación de la Rodilla , Fibrosis , Rango del Movimiento Articular
6.
Am J Transplant ; 23(3): 336-352, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36695693

RESUMEN

Acute rejection (AR) is an important factor that leads to poor prognosis after liver transplantation (LT). Macrophage M1-polarization is an important mechanism in AR development. MicroRNAs play vital roles in disease regulation; however, their effects on macrophages and AR remain unclear. In this study, rat models of AR were established following LT, and macrophages and peripheral blood mononuclear cells were isolated from rats and humans, respectively. We found miR-449a expression to be significantly reduced in macrophages and peripheral blood mononuclear cells. Overexpression of miR-449a not only inhibited the M1-polarization of macrophages in vitro but also improved the AR of transplant in vivo. The mechanism involved inhibiting the noncanonical nuclear factor-kappaB (NF-κB) pathway. We identified procollagen-lysine1,2-oxoglutarate5-dioxygenase 1 (PLOD1) as a target gene of miR-449a, which could reverse miR-449a's inhibition of macrophage M1-polarization, amelioration of AR, and inhibition of the NF-κB pathway. Overall, miR-449a inhibited the NF-κB pathway in macrophages through PLOD1 and also inhibited the M1-polarization of macrophages, thus attenuating AR after LT. In conclusion, miR-449a and PLOD1 may be new targets for the prevention and mitigation of AR.


Asunto(s)
Trasplante de Hígado , MicroARNs , Animales , Humanos , Ratas , Leucocitos Mononucleares/metabolismo , Macrófagos/metabolismo , MicroARNs/genética , FN-kappa B/metabolismo , Procolágeno/metabolismo , Procolágeno/farmacología
7.
Int Immunopharmacol ; 113(Pt B): 109433, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36371863

RESUMEN

Glabridin is an active ingredient extracted from the root of Glycyrrhiza glabra. Previous studies showed that glabridin had potent hepatoprotective effect, however, the effect of glabridin on liver fibrosis and its potential mechanisms remain largely unknown. The present study was aimed to study the effect and potential mechanisms of glabridin on liver fibrosis in carbon tetrachloride (CCl4)-treated mouse livers. Glabridin attenuated the liver injury and improved pathological changes in CCl4-treated mouse livers. Glabridin suppressed the liver fibrosis in CCl4-treated mouse livers, as shown by the decreased collagen deposition, the reduced hydroxyproline level together with the decreased mRNA and protein expression of α-SMA, fibronectin and α1(I)procollagen in mouse livers. Interestingly, glabridin increased the mRNA and protein expression of proliferator-activated receptor gamma (PPARγ) in CCl4-treated mouse livers. In addition, both immunohistochemistry and tissue immunofluorescence showed that glabridin upregulated the expression of PPARγ in CCl4-treated mouse livers. Glabridin evidently reduced the levels of pro-inflammatory factors and increased the level of anti-inflammatory factor in CCl4-treated mouse livers and sera. In addition, Glabridin inhibited the level of MDA and increased the level of GSH as well as the total antioxidant capacity (T-AOC) in CCl4-treated mouse livers. In vitro study showed that glabridin reduced the cell viability of PDGF-BB-stimulated JS-1 cells. Noteworthy, glabridin showed no obvious toxicity on normal JS1 cells. Glabridin inhibited the protein expression of α-SMA, fibronectin and α1(I)procollagen, and increased the expression of PPARγ in stimulated JS-1 cells. Furthermore, disruption of PPARγ attenuated the anti-inflammatory and anti-oxidative stress effects of glabridin in stimulated JS-1 cells. Collectively, glabridin inhibited the liver fibrosis and hepatic stellate cells activation by suppressing inflammation and oxidative stress through activation of PPARγ in carbon tetrachloride-treated mice.


Asunto(s)
Tetracloruro de Carbono , Células Estrelladas Hepáticas , Ratones , Animales , Tetracloruro de Carbono/farmacología , PPAR gamma/metabolismo , Fibronectinas/metabolismo , Procolágeno/metabolismo , Procolágeno/farmacología , Procolágeno/uso terapéutico , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/metabolismo , Inflamación/metabolismo , Hígado/patología , Estrés Oxidativo , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Antiinflamatorios/metabolismo , ARN Mensajero/metabolismo
8.
Am J Hypertens ; 35(2): 156-163, 2022 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-34618887

RESUMEN

BACKGROUND: Previous studies have shown that hydrogen can antagonize the fibrosis of various organs. We investigated whether hydrogen-rich saline (HRS) can attenuate myocardial fibrosis in spontaneously hypertensive rats (SHRs) and clarified the mechanisms involved. METHODS: We examined the effect of HRS and pirfenidone (PFD) on myocardial fibrosis in SHR. Systolic blood pressure, left ventricular mass index (LVMI), and heart weight index (HWI) were measured, Masson trichrome staining was performed. We assessed the role of superoxide dismutase (SOD), malondialdehyde (MDA), Alpha-smooth muscle actin (α-SMA), collagen I, collagen III, and tissue inhibitors of metalloproteinases (TIMPs) in myocardium. We detected the concentrations of procollagen type-I C-terminal propeptide (PICP), procollagen type-III N-terminal propeptide (PIIINP), and angiotensin II (Ang II) in rat serum. Furthermore, the relative protein levels of the transforming growth factor beta (TGF-ß)/Smad pathway were tested. RESULTS: We discovered that HRS decreases LVMI (P < 0.05) and HWI (P < 0.05) in vivo. Compared with model group, HRS decreases the level of collagen volume fraction (P < 0.0001), collagen I (P < 0.001), and collagen III (P < 0.001) in myocardium, and Ang II (P < 0.05), PICP (P < 0.001), and PIIINP (P < 0.05) in serum. In addition, HRS downregulates the expression of MDA (P < 0.01), α-SMA (P < 0.05), and TIMPs (P < 0.05), and increased SOD (P < 0.05). Furthermore, HRS downregulated the expression levels of TGF-ß1 (P < 0.0001), Smad3 (P < 0.0001), and Smad2/3 (P < 0.001), but had no effect on Smad7 expression (P > 0.05). PFD had similar effect compared with HRS and control group. CONCLUSIONS: HRS reduced oxidative stress and improved myocardial collagen content, which may be related to inhibition of the TGF-ß signaling pathway. This suggests that HRS is an effective therapeutic strategy for myocardial fibrosis.


Asunto(s)
Cardiomiopatías , Procolágeno , Angiotensina II/farmacología , Animales , Cardiomiopatías/metabolismo , Colágeno Tipo I/metabolismo , Fibrosis , Hidrógeno/metabolismo , Hidrógeno/farmacología , Miocardio/metabolismo , Procolágeno/metabolismo , Procolágeno/farmacología , Ratas , Ratas Endogámicas SHR , Transducción de Señal , Superóxido Dismutasa/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo
9.
Connect Tissue Res ; 55(1): 20-5, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24437601

RESUMEN

Cartilage is unique in being established as an avascular tissue during development. Cartilage also has the property of being resistant to tumor invasion with tumors arising on the periphery of cartilage and in bone, but sparing the cartilage. These properties have been investigated for many years beginning in the 1970's. Many anti-angiogenic molecules have been isolated from cartilage in small amounts. Portions of molecules from cartilage also possess anti-angiogenic properties when released from the parent protein by degradative extracellular enzymes. This review highlights a new anti-angiogenic and anti-tumor moiety from cartilage, the NH2-propeptide of type IIB collagen. When released from the procollagen during synthesis, the propeptide has the capacity to act on its own to protect the cartilage by killing of endothelial cell, osteoclasts and tumor cells.


Asunto(s)
Colágeno Tipo II/metabolismo , Procolágeno/metabolismo , Secuencia de Aminoácidos , Inhibidores de la Angiogénesis/farmacología , Animales , Antineoplásicos/farmacología , Condrocitos/metabolismo , Condrocitos/patología , Colágeno Tipo II/química , Colágeno Tipo II/farmacología , Humanos , Modelos Biológicos , Datos de Secuencia Molecular , Procolágeno/química , Procolágeno/farmacología
10.
BMC Cancer ; 9: 59, 2009 Feb 18.
Artículo en Inglés | MEDLINE | ID: mdl-19226458

RESUMEN

BACKGROUND: The COOH terminal peptide of Pro-collagen type I (PICP, also called C3) is chemotactic for endothelial melanoma and breast cancer cells. PICP induces the expression of Metalloproteinases-2 and -9, of Vascular endothelial growth factor and of the chemokine CXCL-12 receptor CXCR4 in MDA MB231 breast carcinoma cells in vitro. METHODS: We used a model of xenografts in BalbC/nude mice obtaining tumors by implanting in contro-lateral subcutaneous positions MDA MB231 cells added or not with purified PICP and studied the earlier phases of tumor development, up to 48 days from implant, by histology, immunostain and in situ hybridization. RESULTS: Addition of PICP promotes rapid vascularization of the tumors while does not affect mitotic and apoptotic indexes and overall tumor growth. PICP-treated, relative to control tumors, show up-modulation of Vascular endothelial factor, Metalloproteinase-9 and CXCR4, all tumor prognostic genes; they also show down-modulation of the endogenous Metalloproteinase inhibitor, reversion-inducing-cysteine-rich protein with kazal motifs, and a different pattern of modulation of Tissue Inhibitor of Metalloproteinase-2. These changes occur in absence of detectable expression of CXCL-12, up to 38 days, in control and treated tumors. CONCLUSION: PICP has an early promoting effect in the acquisition by the tumors of prometastatic phenotype. PICP may be play a relevant role in the productive interactions between stroma and tumor cells by predisposing the tumor cells to respond to the proliferation stimuli ensuing the activation of signaling by engagement of CXCR4 by cytokines and by fostering their extravasion, due to the induction of increased vascular development.


Asunto(s)
Neoplasias de la Mama/irrigación sanguínea , Neoplasias de la Mama/patología , Fragmentos de Péptidos/farmacología , Procolágeno/farmacología , Animales , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Quimiocina CXCL12/biosíntesis , Quimiocina CXCL12/genética , Femenino , Expresión Génica/efectos de los fármacos , Humanos , Hibridación in Situ , Metaloproteinasa 2 de la Matriz/biosíntesis , Metaloproteinasa 2 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/biosíntesis , Metaloproteinasa 9 de la Matriz/genética , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Metástasis de la Neoplasia , Neovascularización Patológica/enzimología , Neovascularización Patológica/genética , Neovascularización Patológica/metabolismo , Neovascularización Patológica/patología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Receptores CXCR4/biosíntesis , Receptores CXCR4/genética , Trasplante Heterólogo , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Factor A de Crecimiento Endotelial Vascular/genética
11.
J Neurochem ; 73(5): 1816-27, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10537039

RESUMEN

Schwann cells cloned from rat sciatic nerve survive and display self-induced growth suppression, or undergo spontaneous apoptosis, on long-term serum-free subconfluent culture. Strain SCL4.1/F7 sustained the capacity to growth arrest for up to 40 generations. A soluble activity transmitted between neighbouring cells of this strain suppresses DNA synthesis within three cell cycles. Autocrine Schwann cell growth-inhibitory factor (SGIF) operates during the G1 phase of the cell cycle, overcomes the mitogenic action of Schwann cell/serum-associated (platelet-derived growth factor-BB) and axon-associated (axolemma-enriched fraction) stimuli in serum-free conditions, and suppresses DNA synthesis in sciatic nerve Schwann cell cultures in a stage-specific manner. A 35-kDa protein with N-terminal sequence and approximate molecular mass of the C-propeptide of rat alpha1-procollagen I makes a major contribution to SGIF. Growth suppression in the SCL4.1/F7 strain is mediated by the ras/extracellular signal-regulated kinase pathway, is accompanied by down-regulation of erbB2/erbB3 and of tetraethylammonium-sensitive K+ currents, and is followed by transition of cells within 5-10 days from O4+, p75 nerve growth factor receptor (p75NGF-R)+, glial fibrillary acidic protein (GFAP)+ to O4+, p75NGF-R-, GFAP-, periaxin+ phenotypes. Oct-6/SCIP mRNA is present in both proliferating and growth-arrested SCL4.1/F7 cells. These results demonstrate an autocrine/ paracrine loop for the growth arrest of clonally derived Schwann cells in the absence of axons linked in part to the metabolism of collagen. Schwann cells thus appear to self-regulate growth in a negative as well as a positive direction through characterized molecular mechanisms and signal pathways.


Asunto(s)
Inhibidores de Crecimiento , Fragmentos de Péptidos/farmacología , Procolágeno/farmacología , Células de Schwann/citología , Animales , Becaplermina , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Células Cultivadas , Medios de Cultivo Condicionados , ADN/biosíntesis , Fase G1 , Inhibidores de Crecimiento/análisis , Inhibidores de Crecimiento/farmacología , Mitógenos/farmacología , Vaina de Mielina/fisiología , Factor de Crecimiento Derivado de Plaquetas/farmacología , Canales de Potasio/fisiología , Proteínas Proto-Oncogénicas c-sis , Ratas , Proteínas Tirosina Quinasas Receptoras/metabolismo , Receptor EphA8 , Receptor ErbB-2/metabolismo , Células de Schwann/efectos de los fármacos , Nervio Ciático/citología , Células Madre/citología , Células Madre/efectos de los fármacos , Factores de Tiempo
12.
J Cell Biochem ; 75(2): 206-14, 1999 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-10502293

RESUMEN

Activin-A is a member of the transforming growth factor-beta (TGF-beta) superfamily and is expressed by osteoblasts. However, the role of activin-A on osteoblasts is not clearly understood. We examined the effects of activin-A on osteoblast proliferation or differentiation, and mineralization by the osteoblasts in the first subcultures of fetal rat osteoblasts obtained from calvarial bones. Exogenous activin-A led to impaired formation of bone nodules in a dose-dependent manner, although it did not influence cell proliferation using an MTT assay. This inhibitory effect depended upon the time at which activin-A was added to the culture media, and the effect was most significant when addition took place at the early phase of the culture. In addition, exogenous activin-A inhibited gene expression of type I procollagen, alkaline phosphatase, osteonectin, and osteopontin in the cultured cells using Northern blot analysis. The peak of osteocalcin mRNA was delayed. Gene expression for TGF-beta was not influenced by exogenous activin-A. The betaA subunit (activin-A) mRNA was detected during the early phase of this culture. These results indicate that activin-A inhibited early differentiation of the fetal rat calvarial cells, or osteoblasts.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Inhibinas/farmacología , Osteoblastos/efectos de los fármacos , Cráneo/efectos de los fármacos , Activinas , Fosfatasa Alcalina/farmacología , Animales , Huesos/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Osteocalcina/farmacología , Osteonectina/farmacología , Osteopontina , Procolágeno/farmacología , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Sialoglicoproteínas/farmacología , Cráneo/embriología , Factores de Tiempo
13.
Biochim Biophys Acta ; 1310(1): 97-102, 1996 Jan 10.
Artículo en Inglés | MEDLINE | ID: mdl-9244181

RESUMEN

In this study, we purified C-terminal propeptide of type I collagen (PICP) from the conditioned medium of osteoblastic MC3T3-E1 cells by chromatographic and Agarose gel extraction procedures. PICP was confirmed to be present in bone by Western blotting using a specific antibody, and was proved to be synthesized by osteoblasts with metabolic labeling. PICP promoted cell-attachment of osteoblastic MC3T3-E1 cells. We conclude that PICP is synthesized by osteoblasts and stored in bone, and that it plays a role in the maintenance of bone cells on bone matrix.


Asunto(s)
Osteoblastos/efectos de los fármacos , Fragmentos de Péptidos/biosíntesis , Procolágeno/biosíntesis , Secuencia de Aminoácidos , Animales , Western Blotting , Proteínas Morfogenéticas Óseas/metabolismo , Huesos/metabolismo , Adhesión Celular/efectos de los fármacos , Línea Celular/efectos de los fármacos , Medios de Cultivo/química , Datos de Secuencia Molecular , Osteoblastos/citología , Fragmentos de Péptidos/química , Fragmentos de Péptidos/farmacología , Procolágeno/química , Procolágeno/farmacología , Ratas , Tritio
15.
J Biol Chem ; 268(14): 9941-4, 1993 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-8486721

RESUMEN

The NH2 and COOH propieces of fibril-forming collagens are cleaved off extracellularly and have been implicated in feedback regulation of their own synthesis. Recently, we showed that a subfragment of the carboxyl-terminal propeptide of type I collagen (residues 197-241) dramatically augments extracellular matrix production in subconfluent fibroblasts. This stimulation of type I collagen, type III collagen, and fibronectin production occurred in a dose- and time-dependent manner with no effect on total protein synthesis or on the ratio of secreted proteins to cell-associated proteins (Katayama, K., Seyer, J.M., Raghow, R., and Kang, A.H. (1991) Biochemistry 30, 7097-7104). In the present report, we have extensively dissected this subfragment of the propeptide and found that the pentapeptide Lys-Thr-Thr-Lys-Ser (residues 212-216) is the minimum sequence necessary for potent stimulation of collagen and fibronectin production in a variety of mesenchymal cells. We postulate that the extracellular matrix production in fibroblasts may be subject to either positive or negative feedback regulation depending on the repertoire of specific proteases during postinflammatory tissue regeneration and fibrosis.


Asunto(s)
Matriz Extracelular/fisiología , Fibronectinas/biosíntesis , Fragmentos de Péptidos/farmacología , Procolágeno/biosíntesis , Procolágeno/farmacología , Secuencia de Aminoácidos , Animales , Línea Celular , Células Cultivadas , Embrión de Pollo , Matriz Extracelular/efectos de los fármacos , Humanos , Cinética , Datos de Secuencia Molecular , Factor de Crecimiento Transformador beta/farmacología
16.
J Biol Chem ; 261(30): 14355-60, 1986 Oct 25.
Artículo en Inglés | MEDLINE | ID: mdl-3771535

RESUMEN

We evaluated the effects of a synthetic copy of a highly conserved portion (residues 225-246) of the COOH-propeptide of human pro-alpha 2(I) procollagen on collagen, fibronectin, and total protein synthesis by human fibroblasts. Incubation of COOH-propeptide 225-246 with fibroblasts resulted in a concentration-dependent inhibition of both type I procollagen and fibronectin when compared with controls; a 50% inhibition of both fibronectin and type I collagen was observed at a concentration of 45 microM. Since the overall cellular protein synthesis was only minimally affected, COOH-propeptide appeared to specifically inhibit collagen and fibronectin synthesis. The peptide was nontoxic to cells and the inhibition was completely reversible upon removal of the peptide. We measured the steady-state levels of mRNAs coding for procollagen, fibronectin, and beta-actin by hybridization to specific recombinant cDNA probes; there was no significant change in the steady-state level of mRNAs of the three proteins. These results strongly suggest that the biosynthesis of procollagen and fibronectin in COOH-propeptide-treated cells is inhibited at a post-transcriptional level. These data establish a link between collagen and fibronectin synthesis and further define the important interaction of these molecules in the formation of the extracellular matrix.


Asunto(s)
Colágeno/biosíntesis , Fibronectinas/biosíntesis , Fragmentos de Péptidos/síntesis química , Procolágeno/síntesis química , Secuencia de Aminoácidos , Células Cultivadas , Cromatografía Líquida de Alta Presión , Fibroblastos/metabolismo , Humanos , Pulmón/citología , Pulmón/metabolismo , Fragmentos de Péptidos/farmacología , Procolágeno/farmacología , Transcripción Genética
17.
Biochem J ; 239(2): 311-5, 1986 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-3028370

RESUMEN

Prolyl 4-hydroxylase (EC 1.14.11.2) is an essential enzyme in the post-translational modification of collagen. Inhibitors of this enzyme are of potential interest for the treatment of diseases involving excessive deposition of collagen. We have found that anthraquinones with at least two hydroxy groups ortho to each other are potent inhibitors of this enzyme. Kinetic studies revealed that 2,7,8-trihydroxyanthraquinone (THA) competitively inhibited the co-substrate, 2-oxoglutarate, but was non-competitive with regard to ascorbate and was tentatively considered to be uncompetitive with regard to protocollagen. The inhibition by THA was greatly enhanced in the absence of added Fe2+ and was partially reversed by the addition of concentrations of Fe2+ in excess of the optimum for the enzymic reaction. Binding studies indicated that THA is an effective chelating agent for Fe2+. Several non-quinoidal compounds bearing the catechol moiety also inhibited the enzyme. The results suggest that THA inhibited prolyl 4-hydroxylase by binding to the enzyme at the site for 2-oxoglutarate possibly involving the Fe2+ atom, rather than by complexing with Fe2+ in free solution. The inhibition of prolyl 4-hydroxylase by THA exhibited strong positive co-operativity and may involve three distinct but non-independent binding sites.


Asunto(s)
Antraquinonas/farmacología , Procolágeno-Prolina Dioxigenasa/antagonistas & inhibidores , Animales , Ácido Ascórbico/farmacología , Embrión de Pollo , Hierro/farmacología , Ácidos Cetoglutáricos/farmacología , Cinética , Procolágeno/farmacología , Relación Estructura-Actividad
18.
Biochim Biophys Acta ; 826(2-3): 101-7, 1985 Nov 13.
Artículo en Inglés | MEDLINE | ID: mdl-4052427

RESUMEN

Fragments of the amino-terminal propeptide of procollagen have been shown to inhibit the synthesis of procollagen in cultured cells and in a reticulocyte lysate cell-free system (for review see Timpl, R. and Glanville, R.W. (1981) Clin. Orth. Rel. Res. 158, 224-242). In this report, we show that the full-length amino-terminal propeptide of chick pro alpha1(I) chains inhibits the translation of chick tendon mRNA and rat brain mRNA in a reticulocyte lysate cell-free system. The synthesis of procollagen and non-collagenous proteins was equally affected. Inhibition was dose-dependent up to 10 microM. A similar pattern of inhibition was observed for the collagenase-resistant fragment, col 1(I).


Asunto(s)
Fragmentos de Péptidos/farmacología , Procolágeno/farmacología , Biosíntesis de Proteínas/efectos de los fármacos , Animales , Química Encefálica , Sistema Libre de Células , Pollos , Colágeno/biosíntesis , Colágeno/genética , Retroalimentación , Fragmentos de Péptidos/aislamiento & purificación , Procolágeno/aislamiento & purificación , Procesamiento Proteico-Postraduccional , ARN Mensajero/metabolismo , Ratas , Tendones/análisis
19.
J Invest Dermatol ; 79 Suppl 1: 73s-76s, 1982 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7086193

RESUMEN

Collagen synthesis is a complex orchestration of intracellular and extracellular events. In addition to synthesis of the polypeptide chains more than a dozen modifications of the molecule occur; most of these are enzymatic and specific for collagen. Regulational control of collagen synthesis promises to be equally complex. Examples are described to 4 specific regulatory influences. Ascorbic acid markedly stimulates collagen synthesis without affecting synthesis of other proteins. This effect appears to be unrelated to its cofactor roles for hydroxylation of lysine and proline. Glucocorticoids at microM concentration specifically inhibit collagen synthesis. Tissues treated with glucocorticoids have diminished levels of mRNA for collagen. During collagen synthesis the aminoterminal propeptide of procollagen is cleaved by a specific protease. This peptide appears to be a feedback inhibitor of collagen synthesis. This effect can be demonstrated in cells and in cell-free synthesizing systems. A membrane receptor system may permit the peptide to be recognized and subsequently act as a translational control mechanism. Viral transformation of fibroblasts results in selectively decreased synthesis of collagen. Levels of cytoplasmic and nuclear mRNA are likewise selectively diminished consistent with transcriptional control.


Asunto(s)
Colágeno/biosíntesis , Animales , Ácido Ascórbico/farmacología , Bovinos , Transformación Celular Viral , Células Cultivadas , Embrión de Pollo , Fibroblastos/metabolismo , Glucocorticoides/farmacología , Humanos , Fragmentos de Péptidos/farmacología , Procolágeno/biosíntesis , Procolágeno/farmacología , Ratas , Piel/metabolismo
20.
J Biol Chem ; 254(15): 7016-23, 1979 Aug 10.
Artículo en Inglés | MEDLINE | ID: mdl-457666

RESUMEN

NH2-terminal extension peptides of type I and type III procollagens were isolated from dermatosparactic and normal fetal calfskin, respectively. Cell culture experiments showed that the globular domains of the tested procollagen peptides were biologically active but that peptides from the helical region of collagen had no effect. The peptides were added to the incubation medium of calf fibroblasts along with radioactive precursor amino acids, and the amount of newly synthesized collagen was determined. The experiments indicated that procollagen peptides exerted a feedback-like inhibitory effect specific for the synthesis of collagen. Neither degradation of collagen, hydroxylation of collagen alpha chains, nor synthesis of noncollagenous proteins were affected. Synthesis of type II collagen by calf chondrocytes was not reduced. In addition, it was shown that procollagen peptides from calf were equally effective when added to human fibroblast cultures, an observation that could be of considerable medical interest.


Asunto(s)
Cartílago/metabolismo , Colágeno/biosíntesis , Fragmentos de Péptidos/farmacología , Procolágeno/farmacología , Piel/metabolismo , Animales , Cartílago/efectos de los fármacos , Bovinos , Células Cultivadas , Feto , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Conformación Proteica , Piel/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA